Skip to main content

Advertisement

Table 1 FDA approved therapies

From: Potential new targets for drug development in severe asthma

  Mechanism of Action Biomarker Outcomes Significant Adverse Events References
Omalizumab Blocks IgE interaction to FcεRI ↑FeNO (> 19.5 ppb)
↑Peripheral eosinophils (≥200/uL)
Decreased exacerbations
Reduced IgE levels
Improved quality of life
Cardiovascul ar and cerebrovascu lar event risk Hanania 2013 [6]
Busse 2013 [7]
Casale 2017 [4]
Chipps 2017 [9]
Mepolizumab Anti-IL5 ↑Peripheral eosinophils (> 150 or 300/uL) or sputum eosinophilia (> 3%) Decreased exacerbations
Reduced prednisone dose
Decreased blood and sputum eosinophils
Improved quality of life
Herpes Zoster; Helminth infections Nair 2009 [10]
Pavord 2012 [11]
Liu 2013 [14]
Ortega 2014 [13]
Bel 2014 [12]
Reslizumab Anti-IL5 ↑Peripheral eosinophils (> 400/uL) or sputum eosinophilia (> 3%) Decreased exacerbations
Decreased blood and sputum eosinophils
Improved FEV1
Helminth infections; CPK elevation Castro 2011 [15]
Castro 2015 [16]
Corren 2016 [17]
Benralizumab Anti-IL5Ralpha ↑Eosinophils
↑FeNO
Decreased exacerbations (higher eosinophilia more predictive of response)
Improved FEV1
Helminth infections Castro 2014 [18]
FitzGerald 2016 [19]
Bleecker 2016 [20]